Rectal Cancer
Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)
- Details
ClinicalTrials.gov ID:
NCT04813627
Diagnosis Type:
NA
USOR Number:
- Address
12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708-7600